Optimal sampling time and clinical implication of the SCN5A promoter haplotype in propafenone therapeutic drug monitoring.
Kosuke DokiYuki ShirayamaYukio SekiguchiKazutaka AonumaYukinao KohdaMasato HommaPublished in: European journal of clinical pharmacology (2018)
The present study found that antiarrhythmic efficacy of propafenone was associated with peak propafenone concentration rather than trough concentration and was affected by the SCN5A promoter haplotype.